Evidence map›Paper›PMID 26744525›Full record

ArticleCancer research2016

Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.

Karin A Vineretsky, Margaret R Karagas, Brock C Christensen, Jacquelyn K Kuriger-Laber, Ann E Perry, Craig A Storm, Heather H Nelson

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The Role of Killer Ig-like Receptors in Diseases from A to Z.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Microgravity and immune cells.Journal of the Royal Society, Interface · 2023
    Review
  7. The Immunogenetics of Non-melanoma Skin Cancer.Advances in experimental medicine and biology · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Karin A VineretskyDivision of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Margaret R KaragasDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Brock C ChristensenDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Jacquelyn K Kuriger-LaberMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Ann E PerryDepartment of Pathology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Craig A StormDepartment of Pathology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Heather H NelsonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota. hhnelson@umn.edu.
Dartmouth College · USUniversity of Minnesota · US

Funding

Relation Between In-utero Vitamin D and Immune Function in Early Childhood P20GM104416 · NIGMS · DARTMOUTH COLLEGE · PI CHRISTENSEN, BROCK CLARKE · 2013 to 2022
$23.7M
NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
MOLECULAR EPIDEMIOLOGY OF NON-MELANOMA SKIN CANCERR01CA082354 · NCI · UNIVERSITY OF MINNESOTA · PI NELSON, HEATHER HAMMOND · 1999 to 2011
$4.2M
NCI NIH HHS R01 CA057494NCI NIH HHS R01CA057494NCI NIH HHS R01 CA082354NCI NIH HHS R01CA82354NIGMS NIH HHS P20 GM104416
6 · The paper itself

Abstract

Natural killer (NK)-cell phenotype is partially mediated through binding of killer-cell immunoglobulin-like receptors (KIR) with HLA class I ligands. The KIR gene family is highly polymorphic and not well captured by standard genome-wide association study approaches. Here, we tested the hypothesis that variations in KIR gene content combined with HLA class I ligand status is associated with keratinocyte skin cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). We conducted an interaction analysis of KIR gene content variation and HLA-B (Bw4 vs. Bw6) and HLA-C (C1 vs. C2). KIR centromeric B haplotype was associated with significant risk of multiple BCC tumors (OR, 2.39; 95% confidence interval, 1.10-5.21), and there was a significant interaction between HLA-C and the activating gene KIR2DS3 for BCC (Pinteraction = 0.005). Furthermore, there was significant interaction between HLA-B and telomeric KIR B haplotype (containing the activating genes KIR3DS1 and KIR2DS1) as well as HLA-B and the activating KIR gene KIR2DS5 (Pinteraction 0.001 and 0.012, respectively). Similar but greatly attenuated associations were observed for SCC. Moreover, previous in vitro models demonstrated that p53 is required for upregulation of NK ligands, and accordingly, we observed there was a strong association between the KIR B haplotype and p53 alteration in BCC tumors, with a higher likelihood that KIR B carriers harbor abnormal p53 (P < 0.004). Taken together, our data suggest that functional interactions between KIR and HLA modify risks of BCC and SCC and that KIR encoded by the B genes provides selective pressure for altered p53 in BCC tumors.

Indexed as

AgedBasal Cell CarcinomaCarcinoma, Squamous CellCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHLA-C AntigensHumansKiller Cells, NaturalMaleMiddle AgedReceptors, KIRSkin NeoplasmsHLA-C AntigensKIR2DS1 protein, humanReceptors, KIR

Identifiers

PMID26744525
PMCPMC4715977
OpenAlexW2225261815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.